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Moderate-to-severe atopic dermatitis (AD) often
requires systemic treatments with immunomodula-
tory drugs. Unfortunately, systemic agents currently
used for AD have extensive side effects, and
many patients experience suboptimal therapeutic
responses. Additionally, many of these treatments,
such as cyclosporine A, can only be used for a limited
time because of potentially deleterious side effects.
Novel targeted treatments are now moving into
clinical trials for AD, including ustekinumab.1,2
CASE REPORT
A 70-year-old, 58-kg white woman presented to
the clinic in January 2014 with worsening chronic
AD. She reported worsening pruritus and scaly,
erythematous patches on her neck, trunk, and
extremities (Fig 1). Her medical history was also
significant for allergic contact dermatitis, with
positive patch tests for propylene glycol,
formaldehyde-releasers, and tea tree oil. Her recent
worsening was not believed to be related to her
concomitant allergic contact dermatitis.
The patient had moderate-to-severe AD for 26
years, had tried numerous topical steroids with
minimal benefit, and failed to show sustained
improvement on narrow band ultraviolet B therapy.
She initially responded to treatment with 300mg/d of
cyclosporine A, but her disease flared after 1 year,
and no further improvement was achieved after
adding mycophenolate, 2 g/d to her regimen for 1
month. At this time, the patient was started on 45 mg
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The patient showed impressive improvement in
erythema, lichenification, and pruritus after only 2
treatments and clearance at week 19 (Fig 2). The
SCORAD (SCORing Atopic Dermatitis), which
accounts for objective and subjective symptoms,
was performed as part of the examination at each
visit. The patient’s scores decreased from 50 to 10 at
week 8, remained at 10 at week 11, and decreased to
0 at week 19. After 4 doses of ustekinumab, the
patient reached clearance at week 19.DISCUSSION
Ustekinumab is a human monoclonal antibody
targeting the p40 subunit of interleukin (IL)-12/23,
effectively blocking the IL-23/T helper cell 17 (Th17)
pathway,3 and is approved by the US Food and Drug
Administration for moderate-to-severe psoriasis.
AD is increasingly recognized as a Th2- and
Th22-centered disease with some contributions of
Th17 and Th1 axes.4 IL-23 is believed to promote
expansion of Th17 and Th22 T cells, and Th17
T cells have been reported recently to play a role
in acute AD lesions.5 Thus, by blocking IL-23 in AD
with ustekinumab, Th17 and Th22 pathways are
inhibited.3 Few reports describe beneficial effects ofMedical Center, 5 East 98th Street, 5th floor Box 1048, New York,
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Fig 1. Initial scaly, erythematous patches. Fig 2. Drastic improvement at week 19 of ustekinumab
treatment.
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improvement of AD disease activity with ustekinu-
mab given in shorter time intervals in a refractory
patient. Based on anecdotal experience at our
institution, AD tends to exacerbate 1 to 2 weeks
before the expected ustekinumab dose if the
standard psoriasis dose is used. Thus, we wanted
to evaluate shorter dosing intervals. Our report
highlights the possible efficacy of targeting Th17/
IL-23 in AD, and, unlike with psoriasis, effective
treatment of AD with ustekinumab may require
shorter dosing intervals, but this still needs to be
evaluated in large clinical trials. The Th17/IL-23
cytokines are promising therapeutic targets, with
hopes for further investigation into their possible
role in AD therapeutics.REFERENCES
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